Rapid Micro Biosystems: Benefiting From Partnership With Merck; Initiating With 'Buy'

  • Initiating Rapid Micro Biosystems at 'buy' with $4.60 fair value, driven by strong growth potential in automated microbial quality control market. Growth Direct platform offers clear advantages over manual MQC, with automation, regulatory benefits, and a $10B addressable market opportunity. Merck partnership is a key catalyst, enabling global distribution, supply chain optimization, and improved gross margins for Rapid Micro Biosystems.